[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer

NCT ID: NCT02297386

Last Updated: 2018-08-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-11-30
• Study Completion Date: 2018-08-31

Brief Summary

The purpose of this study is to test the ability of a new PET scan radiotracer, called FDHT (stands for [18F] Dihydro-Testosterone), to better find and monitor prostate cancer. Radiotracers are a type of drug that carries small amounts of radioactivity that can be seen by the PET scanner. FDHT is a radiotracer that looks for a protein which is present in almost all prostate cancer cells. The investigators want to find out if we can find and monitor changes in cancer using a FDHT PET scan.

Conditions

Prostate Cancer; Localized Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

[18F] DIHYDRO-TESTOSTERONE PET

The diagnostic intervention of this study is the use of FDHT PET in localized prostate cancer. Patients will undergo a 30 minute dynamic scan of the pelvis followed by a whole body scan of approximately 30-minutes duration. The dynamic scan will be optional, but strongly encouraged. PET scanning will preferably be done on the GE Discovery STE PET/CT scanner or the equivalent generation of scanner. The PET scans are routinely "quantitative," that is corrected for attenuation and scatter and adjusted for system sensitivity and providing parametric images in terms of standardized uptake values (SUV) (= μCi found/gm tissue / μCi injected/gm body mass).

Group Type: EXPERIMENTAL

[18F] DIHYDRO-TESTOSTERONE

Intervention Type: DRUG

PET scan

Intervention Type: DEVICE

MRI

Intervention Type: DEVICE

Blood draw

Intervention Type: OTHER

Interventions

[18F] DIHYDRO-TESTOSTERONE

Intervention Type: DRUG

PET scan

Intervention Type: DEVICE

MRI

Intervention Type: DEVICE

Blood draw

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Male aged 21 years or older and below 80 years of age.
• Signed written informed consent and willingness to comply with protocol requirements.
• Histologically confirmed diagnosis of prostate cancer.
• Staging imaging workup including a baseline MRI of the prostate and pelvis performed at MSKCC.
• Baseline imaging to rule out distant metastatic disease (99mTc bone scan, NaF PET, total body MRI, or CT chest/abdomen/pelvis)
• Karnofsky performance status ≥ 70
• Clinical criteria required to be eligible:

a. One of the following i.Pre-treatment PSA ≥10 ng/dL, OR ii. Clinical T-stage assessed by digital rectal exam of ≥T2a, OR ii . Radiographic ≥T3a on MRI, OR iv. Gleason score of ≥3+4=7 c. Visible intraprostatic tumor foci ≥1 cm in largest dimension on T2-weighted images based on initial pre-treatment MRI

• Physician recommendation of ADT.

Exclusion Criteria

• Metastatic disease on standard staging imaging (beyond regional lymph node involvement).

o Absence of metastatic disease (beyond regional lymph node involvement) as defined by a negative bone scan, NaF PET, CT chest/abdomen/pelvis, or total body MRI.

• Prior treatment of the prostate gland for malignant conditions (surgery, cryotherapy, radiotherapy, or photodynamic therapy).
• Physician prescription of androgen receptor antagonist therapy (examples: bicalutamide, flutamide, or enzalutamide) during time of protocol scans.

o Note: ADT consists of chemical castration (i.e. degarelix) to remove endogenous DHT. Androgen receptor antagonists will bind to the androgen receptor and inhibit FDHT from binding.

• Patients receiving testosterone supplementation .
• Any contraindication to baseline MRI based on departmental MR questionnaire, or inability to cooperate for an MRI scan.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to FDHT.
• Hepatic laboratory values:

1. Bilirubin >1.5 x ULN (institutional upper limits of normal)

2. AST/ALT >2.5 x ULN

3. Albumin <2 g/dL

• Creatinine >2.5 mg/dL
• Calcium >11 mg/dL
• Other serious illness(es) which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Joseph Osborne, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Countries

United States

Related Links

http://www.mskcc.org/

Memorial Sloan Kettering Cancer Center

Other Identifiers

14-185

Identifier Type: -

Identifier Source: org_study_id